These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

391 related items for PubMed ID: 23532738

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
    Hodgson MC, Astapova I, Hollenberg AN, Balk SP.
    Cancer Res; 2007 Sep 01; 67(17):8388-95. PubMed ID: 17804755
    [Abstract] [Full Text] [Related]

  • 25. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
    Yoshida T, Kinoshita H, Segawa T, Nakamura E, Inoue T, Shimizu Y, Kamoto T, Ogawa O.
    Cancer Res; 2005 Nov 01; 65(21):9611-6. PubMed ID: 16266977
    [Abstract] [Full Text] [Related]

  • 26. Bicalutamide demonstrates biologic effectiveness in prostate cancer cell lines and tumor primary cultures irrespective of Her2/neu expression levels.
    Gravina GL, Festuccia C, Millimaggi D, Tombolini V, Dolo V, Vicentini C, Bologna M.
    Urology; 2009 Aug 01; 74(2):452-7. PubMed ID: 19285710
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. 1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells.
    Serda RE, Bisoffi M, Thompson TA, Ji M, Omdahl JL, Sillerud LO.
    Prostate; 2008 May 15; 68(7):773-83. PubMed ID: 18247401
    [Abstract] [Full Text] [Related]

  • 29. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.
    Liu C, Armstrong CM, Lou W, Lombard AP, Cucchiara V, Gu X, Yang JC, Nadiminty N, Pan CX, Evans CP, Gao AC.
    Mol Cancer Ther; 2017 Aug 15; 16(8):1521-1530. PubMed ID: 28500234
    [Abstract] [Full Text] [Related]

  • 30. Combination therapy of antiandrogen and XIAP inhibitor for treating advanced prostate cancer.
    Danquah M, Duke CB, Patil R, Miller DD, Mahato RI.
    Pharm Res; 2012 Aug 15; 29(8):2079-91. PubMed ID: 22451249
    [Abstract] [Full Text] [Related]

  • 31. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.
    BJU Int; 2012 Oct 15; 110(8):1149-55. PubMed ID: 22369348
    [Abstract] [Full Text] [Related]

  • 32. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S, Agoulnik IU, Weigel NL.
    Prostate; 2005 Sep 01; 64(4):362-72. PubMed ID: 15754350
    [Abstract] [Full Text] [Related]

  • 33. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.
    Seaton A, Scullin P, Maxwell PJ, Wilson C, Pettigrew J, Gallagher R, O'Sullivan JM, Johnston PG, Waugh DJ.
    Carcinogenesis; 2008 Jun 01; 29(6):1148-56. PubMed ID: 18487223
    [Abstract] [Full Text] [Related]

  • 34. Up-regulation of insulin-like growth factor-binding protein 3 by 5-fluorouracil (5-FU) leads to the potent anti-proliferative effect of androgen deprivation therapy combined with 5-FU in human prostate cancer cell lines.
    Kawabata R, Oie S, Takahashi M, Kanayama H, Oka T, Itoh K.
    Int J Oncol; 2011 Jun 01; 38(6):1489-500. PubMed ID: 21455575
    [Abstract] [Full Text] [Related]

  • 35. Synthesis and preliminary investigations into novel 1,2,3-triazole-derived androgen receptor antagonists inspired by bicalutamide.
    Altimari JM, Niranjan B, Risbridger GP, Schweiker SS, Lohning AE, Henderson LC.
    Bioorg Med Chem Lett; 2014 Nov 01; 24(21):4948-53. PubMed ID: 25301770
    [Abstract] [Full Text] [Related]

  • 36. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T, Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group.
    J Urol; 2008 Sep 01; 180(3):921-7. PubMed ID: 18635218
    [Abstract] [Full Text] [Related]

  • 37. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.
    Malinowska K, Neuwirt H, Cavarretta IT, Bektic J, Steiner H, Dietrich H, Moser PL, Fuchs D, Hobisch A, Culig Z.
    Endocr Relat Cancer; 2009 Mar 01; 16(1):155-69. PubMed ID: 19011039
    [Abstract] [Full Text] [Related]

  • 38. Synergistic killing effect of chloroquine and androgen deprivation in LNCaP cells.
    Kaini RR, Hu CA.
    Biochem Biophys Res Commun; 2012 Aug 24; 425(2):150-6. PubMed ID: 22819840
    [Abstract] [Full Text] [Related]

  • 39. Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients.
    Sekino Y, Oue N, Mukai S, Shigematsu Y, Goto K, Sakamoto N, Sentani K, Hayashi T, Teishima J, Matsubara A, Yasui W.
    Prostate; 2019 Feb 24; 79(2):234-242. PubMed ID: 30324761
    [Abstract] [Full Text] [Related]

  • 40. Comparison of gene expression in LNCaP prostate cancer cells after treatment with bicalutamide or 5-alpha-reductase inhibitors.
    Bühler P, Fischer T, Wolf P, Gierschner D, Schultze-Seemann W, Wetterauer U, Elsässer-Beile U.
    Urol Int; 2010 Feb 24; 84(2):203-11. PubMed ID: 20215827
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.